 (1).png)
SEARL Secures DRAP Approval for Denosumab Injections in Pakistan
Karachi, September 1, 2025 –
The Searle Company Limited (PSX: SEARL) gained momentum at the Pakistan Stock Exchange on Monday, with its share price closing at Rs.114.04, up by 3.64%, after announcing a key regulatory approval.
In a notice to PSX, SEARL confirmed it has successfully obtained registration from the Drug Regulatory Authority of Pakistan (DRAP) for Denosumab injections (120mg and 60mg), a biosimilar drug used in osteoporosis treatment and oncology care.
The approval has been granted under a licensing agreement with Mabwell Pharmaceuticals, China, making SEARL the exclusive registration holder and authorized marketer for these biosimilars in Pakistan.
“This milestone strengthens our product portfolio and reflects our commitment to expanding access to advanced therapies in Pakistan. The commercial launch preparations are already underway,” SEARL stated.
Founded in 1965, SEARL is a subsidiary of International Brands (Private) Limited, which holds 50.25% of its outstanding shares. The company manufactures and markets pharmaceutical, consumer health, and nutritional products across Pakistan.
This latest development follows the appointment of Tahir Ahmed as CEO in July 2025 and signals SEARL’s continued focus on growth, innovation, and shareholder value.
-ltd-reports-strong-halfyearly-results-–-profit-surged)
)
Add a comment